Enzalutamide added to ADT appears to be beneficial for patients with both low-volume and high-volume mHSPC. Similarly, available evidence suggests that apalutamide plus ADT is also beneficial in patients with mHSPC regardless of disease volume.
Learn more about treatment options for metastatic prostate cancer.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Bradley Schwartz, Daniel S. Schwartz. Fast Five Quiz: Metastatic Hormone-Sensitive Prostate Cancer Treatment - Medscape - Jun 27, 2022.